COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05067933

None

None

2021-10-05

Completed

RCT

Randomized

Sequential assignment

Blind label

multi-center

Prevention

inclusion criteria 18 - 75 years of age (inclusive) at the time of signing the informed consent form (icf). cohort 1 only - naive of any prior vaccination for the prevention of covid-19 (tested using a rapid antibody test) at screening and within 7 days prior to the enrollment (day 1). cohort 2 only - have received prior immunizations (both doses) with an eua or fda approved mrna vaccine for the prevention of covid-19, at least 6 months prior to enrollment (day 1). in stable and good health, without significant medical illness, based on medical history, physical examination, vital signs, and clinical laboratory tests as determined by the investigator. safety laboratory values1 within the following range criteria at screening: laboratory values within normal range or grade 1 outside the range of normal with no clinical significance (ncs) for the following analytes:, alanine aminotransferase (alt), aspartate aminotransferase (ast), and bilirubin, blood urea nitrogen (bun), creatinine, glucose, potassium, and sodium laboratory values within normal range for platelet counts2 and the following coagulation tests: pt/inr, aptt and fibrinogen body mass index (bmi) between 17 and 32 kg/m2 at screening. capable of providing signed informed consent. available for all planned visits and phone calls, and willing to complete all protocol-defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per vaccine dose). gender and reproductive considerations male or female participants. contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. refer to appendix 4 (section 9.4). female participants must not be breastfeeding and must have a negative pregnancy test at screening and before each vaccination and fulfill one of the following criteria: at least 1 year post-menopausal (defined as amenorrhea for ≥12 consecutive months prior to screening without an alternative medical cause). women under 60 years will need to verify post-menopausal status via a follicle-stimulating hormone (fsh) test if another option to prevent potential pregnancy will not be utilized for 30 days prior to baseline vaccination and until 60 days after the last vaccination. surgically sterile use of oral, implantable, transdermal or injectable contraceptives for 30 days prior to initial vaccination and until 60 days after the last vaccination. a reliable form of contraception must be approved by the investigator (e.g., double barrier method, depo-provera, intrauterine device, norplant, oral contraceptives, contraceptive patches). not be sexually active (abstinent) or be in a relationship with partner who is sterile (must be discussed with site staff and documented). exclusion criteria medical conditions clinically significant acute illness within 72 hours prior to vaccination defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical exam) (assessment may be repeated during screening period). current or known previous infection with sars-cov-2 or receipt of any therapeutic for the prevention or treatment of covid-19, middle east respiratory syndrome (mers), or severe acute respiratory syndrome (sars). [eua or fda approved mrna vaccines for the prevention of sars-cov-2 infection taken at least 6 months prior to enrollment are permitted in cohort 2] individuals with the following underlying medical conditions who are at higher risk (or might be at higher risk) of severe illness from covid-19 per the guidance from the centers for disease control and prevention (cdc): cancer, including history of cancer or treatment within past 3 years (excluding basal cell carcinoma or squamous cell carcinoma) chronic kidney disease chronic obstructive pulmonary disease (copd) immunocompromised state from solid organ transplant, or other medical condition serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies sickle cell disease uncontrolled type 2 diabetes mellitus asthma (moderate to severe) cerebrovascular disease cystic fibrosis uncontrolled hypertension or high blood pressure immunocompromised state from blood or bone marrow transplant, immune deficiencies, hiv, use of corticosteroids, or use of other immune weakening medicines neurologic conditions, such as dementia liver disease pregnancy or breast feeding pulmonary fibrosis chronic smoking (≥ 1 cigarette per day) thalassemia type 1 diabetes mellitus diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic. any condition that resulted in the absence or removal of the spleen. any other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a participant participating in the study, would render the participant unable to comply with the protocol or would interfere with the evaluation of the study endpoints. diagnostic assessments temperature ≥38.0ºc (100.4°f) within 24 hours prior to the planned study vaccination (assessment may be repeated during screening period). positive hiv, hepatitis b surface antigen (hbsag) or hcv tests at the screening visit. history of gastrointestinal bleeding (e.g. melena or hematochezia) prior/concurrent therapy note: the active period is defined as the time period from day 1 through week 8, or 4 weeks post last vaccination. receipt of a licensed influenza vaccine within 14 days prior to baseline vaccination or another licensed vaccine within 28 days prior to baseline vaccination, or planned administration during the study active period. use of antiviral medications , including anti-retrovirals within 1 week before vaccination or planned use during the active study period. use of antibiotics, proton pump inhibitors, h2 blockers or antacids within 1 week before vaccination or planned use during the active study period. use of medications known to affect the immune function (e.g., systemic corticosteroids and others) within 14 days before vaccination or planned use during the active study period. daily use of nonsteroidal anti-inflammatory drugs, sulfonylureas, and angiotensin ii blockers within 1 week before vaccination or planned use during the active study period. positive urine drug screen for drugs of abuse at screening (except for previous marijuana use); concurrent or planned use of marijuana during the active study period. administration of any investigational vaccine, drug or device within 8 weeks preceding vaccination, or planned use within the duration of the study. other exclusions donation or use of blood or blood products within 4 weeks prior to vaccination or planned donation during the study period. any significant hospitalization within the last year which in the opinion of the investigator or sponsor could interfere with study participation. history of drug, alcohol or chemical abuse within 1 year of screening. history of hypersensitivity or allergic reaction to any component of the investigational vaccine, including but not limited to fish gelatin. any of the following history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia: family or personal history of bleeding or thrombosis history of heparin-related thrombotic events, and/or receiving heparin treatments history of autoimmune or inflammatory disease presence of any of the following conditions known to increase risk of thrombosis within 6 months prior to screening: recent surgery other than removal/biopsy of cutaneous lesions immobility (confined to bed or wheelchair for 3 or more successive days) head trauma with loss of consciousness or documented brain injury receipt of anticoagulants for prophylaxis of thrombosis recent clinically significant infection

None

6

Vaxart

18

75

United States

Healthy volunteers

N/A

66

Rate of Solicited Symptoms of Reactogenicity Collected via a Diary Card (Part 1 and Part 2);Rate of Solicited Symptoms of Reactogenicity Collected via a Diary Card (Part 1 and Part 2);Rate of Unsolicited Adverse Events (Part 1 and Part 2);Rate of Unsolicited Adverse Events (Part 1 and Part 2);Serious Adverse Events (SAEs) and Medically Attended Adverse Events (MAAEs)

None

Phase 2

[{"arm_notes": "Part 1: Na\u00efve, low dose, young adult (18-55 yrs) ", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part 1: Na\u00efve, high dose, young adult (18-55 yrs)", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part 1: Na\u00efve, low dose, older adult (56-75 yrs) ", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part 1: Na\u00efve, high dose, older adult (56-75 yrs)", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part 1: Prior vaccinated, low dose, young adult (18-55 yrs)", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part 1: Prior vaccinated, high dose, young adult (18-55 yrs) ", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part 1: Prior vaccinated, low dose, older adult (56-75 yrs) ", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part 1: Prior vaccinated, high dose, older adult (56-75 yrs) ", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part 2: Repeat dose vaccinations with VXA-CoV2-1.1-S at dose selected from Part 1 ", "treatment_id": 1949, "treatment_name": "Vxa-cov2-1.1-s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]